Advertisement

Topics

Opinion: Combination immunotherapy may have failed in the Incyte/Merck trial, but it’s here to stay

04:40 EDT 23 Apr 2018 | STAT

Greater reliance on precision medicine and biomarkers will improve the testing of combination immunotherapy for cancer.

Original Article: Opinion: Combination immunotherapy may have failed in the Incyte/Merck trial, but it’s here to stay

NEXT ARTICLE

More From BioPortfolio on "Opinion: Combination immunotherapy may have failed in the Incyte/Merck trial, but it’s here to stay"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...